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Left ventricular (LV) failure can be divided into systolic and diastolic dysfunction. The former is characterized by a reduced
ejection fraction and an enlarged LV chamber, the latter by an increased resistance to filling with increased filling
pressures. Systolic dysfunction is clinically associated with left ventricular failure in the presence of marked cardiomegaly,
while diastolic dysfunction is accompanied by pulmonary congestion together with a normal or only slightly enlarged ven-
tricle. Echocardiography is currently the most relevant technique for non-invasive differentiation of the two forms.
Systolic dysfunction is easily assessable by estimation of global ejection fraction and regional wall motion. Diastolic
dysfunction can be diagnosed indirectly by means of a normal or nearly normal ejection fraction and changes of the mitral
filling pattern in the context of LV failure. For an exact determination ofdiastolic dysfunction LV catheterization is required.
Systolic dysfunction treatment is well defined, consisting of ACE inhibitors, followed by diuretics and digitalis.
Calcium channel blockers are usually contraindicated. Diastolic dysfunction therapy is more dependent on the underlying
disease. Calcium channel blockers, ACE inhibitors or beta-blockers are first line drugs in most instances: diuretics can be
added with increasing symptoms. Digitalis should be avoided, except in atrial fibrillation, to control heart rate.
Introduction
Chronic heart failure (CHF) is generally associated with a
poor prognosis, with the annual mortality rate ranging
between 20 and 50% depending on the severity of cardiac
dysfunction'1'. Heart failure has been subdivided into dif-
ferent forms such as forward and backward failure, high-
and low-output failure, systolic or diastolic dysfunction etc.
All these entities show considerable variations in regard to
clinical course and prognosis During the last two decades,
the role of diastolic dysfunction in the development of
heart failure has been increasingly recognized. The differ-
ent pathophysiology of systolic and diastolic dysfunction
affects prognosis and therapeutic management.
Definition and aetiology
Systolic dysfunction is determined by an impaired pump
function with reduced ejection fraction and an enlarged
end-diastolic chamber volume'21. Diastolic dysfunction is
characterized by an increased resistance to filling with
increased filling pressures'2'. Isolated systolic dysfunction is
rare; most patients with CHF have predominating systolic
dysfunction with some degree of diastolic impairment. The
main aetiology of systolic dysfunction is coronary artery
disease followed by hypertensive heart disease'3'4'. Other,
but less frequent causes are dilated cardiomyopathy and
myocarditis Left ventricular (LV) failure is caused by iso-
lated diastolic dysfunction in up to 40% of all cases'51,
mainly due to long-standing hypertension!3'4'. Coronary
artery disease is secondary, hypertrophic cardiomyo-
pathy, restrictive cardiomyopathies and aortic valve
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diseases are less frequent. Age also has a bearing on
physiological diastolic dysfunction'6!.
Pathophysiology
The pathophysiology of systolic dysfunction begins with
a reduction in systolic pump function following a loss of
muscle cells, a decrease in myocardial contractility, and/or
structural changes of the myocardium with an increase in
interstitial fibrosis (= myocardial remodelling). The con-
secutive fall in cardiac output is counteracted by two major
compensatory mechanisms, the Frank-Starling mechanism
and activation of the sympathetic nervous system'71. The
Frank-Starling mechanism leads to an enlargement of the
Table 1 The three major diastolic functional abnormalities and
their main aetiology
Slowed or incomplete relaxation
hypertrophy
asynchrony
ischaemic
Reduced LV filling
early diastolic filling:
delayed relaxation
asynchrony
late diastolic filling:
restrictive filling pattern
chamber dilatation
Accumulation of collagen—altered collagen architecture
(increased myocardial stiffness)
hypertrophy
hypertension
infarction
chamber dilatation
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Figure 1 Photomicrographs (magnification X 300 and repro-
duced here at 80%) of different patterns of collagen accumulation
and altered collagen architecture. Differently orientated collagen
fibres are represented by white or blue in the polarized light micro-
scope. (A) Normal myocardium with few, tiny collagen fibres. (B)
Biopsy sample from a patient with aortic valve disease showing an
increase in interstitial collagen fibres, which are mostly orientated
longitudinally to muscle fibres. (C) Biopsy sample from another
patient with aortic valve disease. The collagen concentration is
increased with evidence of extensive malalignment of collagen
fibres (= cross-hatching).
chamber and an increase in end-diastolic pressure.
Sympathetic activation results in an increase in the heart's
inotropic and chronotropic state. The adverse effects of
these compensatory mechanisms—higher wall stress and
higher oxygen requirements—are reduced by subsequent
myocardial hypertrophy, activation of the baroreceptor
reflex and release of atrial natriuretic peptide. The barore-
ceptor reflex inhibits sympathetic activation and atrial
natriuretic peptide exerts diuretic and vasodilating effects.
During the development of chronic heart failure, these pri-
mary and secondary compensatory mechanisms lose their
beneficial influences, for instance by a down-regulation of
the beta-receptors and dysfunction of the baroreceptor
reflex. A vicious circle evolves, which is enhanced by
increasing activation of the renin-angiotensin system and
by the release of vasopressin, with subsequent vasocon-
striction and water retention.
The pathophysiology of diastolic dysfunction is gener-
ally more diverse, depending on the underlying disease.
Factors extrinsic to the ventricular chamber, such as peri-
cardial constriction or ventricular interdependence must
be distinguished from those intrinsic to the chamber181.
There are three major diastolic functional abnormalities,
namely slowed or incomplete relaxation, reduced LV fill-
ing, and altered passive elastic properties, especially due to
accumulation of collagen or altered collagen architecture
(Table I)'9'. On the cellular level, an increase in myocyte
calcium content, a decrease in ATP levels and an activation
of angiotensin II seem to be responsible for impaired relax-
ation!101. Alterations of the passive elastic properties are
probably the result of enhanced interstitial fibrosis and
changes in the collagen structure. A change in the collagen
architecture with an abnormal alignment (cross-hatching)
and/or endomyocardial fibrosis appears to be responsible
for an increase in myocardial stiffness, whereas the sole
increase in collagen leaves passive diastolic function
unaltered (Figs 1 and 2)'ll>.
LV diastolic dysfunction results in an elevation of ven-
tricular and atrial filling pressures, with consecutive pul-
monary congestion. In this situation, atrial contraction
becomes more important'121. Chronic atrial enlargement
favours the onset of atrial fibrillation. This is poorly toler-
ated in patients with diastolic dysfunction and results often
in acute CHF181. An accompanying tachycardia contributes
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Figure 2 Plot of the constant of myocardial stiffness (b) vs the
total collagen volume fraction in normals and patients with aortic
valve disease and different amounts of myocardial collagen and/or
architecture. The relationship is exponential and increases only
slightly from normal (O) to enhanced myocardial collagen volume
fraction (•) , but increases significantly in the presence of cross-
hatching and/or endomyocardial fibrosis (x). Likewise, isolated
cross-hatching and/or endomyocardial fibrosis ( • left upper
point) is associated with a significant increase of myocardial stiff-
ness Reproduced with permission from the American College of
Cardiology!"].
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phase I: phase II: phase III:
Systolic compensation Systolic compensation
with diastolic failure
Systolic and diastolic
failure
Systole Diastole Systole Diastole Systole Diastole
Figure 3 Pressure (P)-time relationship of the left ventricle in successive phases during the pathophysiological evolution
of pressure or volume overloading, or both (modified from Brutsaert et ai'131, reproduced with permission). There are three
different phases. (1) Systolic compensation: prolonged contraction leads to retarded (but not prolonged) relaxation with
shortening of diastole. (2) Systolic compensation with diastolic failure; impaired relaxation and increased myocardial stiff-
ness occur resulting in elevated left ventricular diastolic pressures. (3) Systolic and diastolic failure: in a third phase, systolic
failure develops.
to diastolic failure by shortening of diastolic filling time.
During the clinical course, chronic mechanical overload
and subendocardial hypoperfusion induce further hyper-
trophy and interstitial fibrosis (= myocardial remodelling)
and finally systolic dysfunction may occur. According to
Brutsaert and co-workers!131 three phases can be distin-
guished in the evolution of diastolic dysfunction in patients
with chronic pressure and volume overload (Fig. 3).
Initially a prolongation of systolic contraction is associated
with retarded relaxation, which shortens diastolic filling
time. In a second phase, impairment of myocardial relax-
ation occurs, which (along with increased stiffness and ele-
vated heart rate) may result in enhanced diastolic filling
pressures. In a third phase, concomitant systolic dysfunc-
tion develops.
Clinical symptoms and diagnostic approach
In clinical practice, systolic dysfunction is characterized
by the occurrence of CHF in the presence of marked car-
diomegaly. Diastolic dysfunction is associated with pul-
monary congestion and a normal or only slightly enlarged
ventricle.
Echocardiography is currently the most relevant non-
invasive method for differentiation of systolic and diastolic
dysfunction. Systolic performance of the ventricle can be
quantified by regional and global function parameters such
as LV-ejection fraction'1*1 and regional wall motion analy-
sis. In contrast, diastolic function cannot be estimated
directly because the measurable filling parameters are a
function of multiple determinants. Diastolic dysfunction is
often associated with typical, but non-specific, mitral filling
patterns (Fig. 4), such as the pattern of delayed relaxation
with increased isovolumic relaxation time and a low E/A
ratio, and the restrictive pattern with shortened isovolumic
relaxation time and a high E/A ratio'151.
During the course of progressive diastolic dysfunction,
mitral filling may shift from the first to the second pattern
with a 'pseudonormalization' in between. Additional infor-
mation for interpretation of mitral filling pressures may be
gained from the pulmonary venous flow velocity pattern
and the colour Doppler M-mode display of mitral inflow1151.
Radionuclide angiography, another non-invasive diagnos-
tic method, has similar advantages and limitations in the
assessment of diastolic dysfunction.
Only LV catheterization allows reliable assessment of
LV diastolic function and differentiates between abnormal
Delayed relaxation
Pseudonormalization
Restrictive pattern
A
Figure 4 Typical, but non-specific mitral filling patterns in dias-
tolic dysfunction. The pattern of delayed relaxation is character-
ized by a low amplitude of the E-wave due to a reduced early left
ventricular filling: E/A-ratio<l. In the course of diastolic dysfunc-
tion, a 'pseudonormalization' with a 'normal' E/A-ratio (>1) can
occur. In advanced forms of diastolic dysfunction a restrictive pat-
tern with a high E-wave, a small A-wave and an increased E/A-
ratio (>2) can be observed.
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Additional therapy
Diuretic*
beta-bloeker
(lowdow)
Beta-blocker
(low dote)
Ventricular
tachycardia
amiodarone
LowEF:
anticoagulation
Implan table
cardioverter
defibrillator
Standard therapy
I Asymptomatic
Mild to moderate symptoms
Severe ivmptoms
Treatment failure
ACE inhibitor
ACE inhibitor
ACE inhibitor
+Di ure tics
+Digitaha
Cardiac
transplantation
Figwe 5 Therapeutic strategies based on clinical symptoms in patients with
systolic dysfunction.
relaxation and altered passive elastic properties. LV relax-
ation can be quantified from the rate of LV pressure decay,
and LV stiffness from the simultaneous pressure-volume
(chamber stiffness) or stress-strain (myocardial stiffness)
relationship. For clinical purposes this differentiation is
rarely necessary, but might help to define the severity of
diastolic dysfunction in individual patients.
Prognosis
The prognosis of systolic dysfunction is poor, with a 5-
year survival rate close to 40% in most studies, compared
to 70% in patients with isolated diastolic dysfunction'41.
Diastolic dysfunction often precedes systolic dysfunction
and represents an early form of heart failure, not necessar-
ily accompanied by clinical symptoms. However, when sys-
Additional therapy Standard therapy
I Asymptomatic
Diuretics Mild to moderate symptoms • ^
Atrial fibrillation:
an ti coagulation +
restoration of
sinus rhythm
Severe symptoms
Treatment failure
C alau m-channel
blocker or ACE
inhibitor or
beta-blocker
Ca 1 d u m-ch annel
blocker or ACE
inhibitor or
beta-blocker
Calcium-channel
blocker and/or
ACE inhibitor +
diuretics
Cardiac
transplantation
Figure 6 Therapeutic strategies based on clinical symptoms in patients with
diastolic dysfunction, such as in hypertensive heart disease.
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tolic dysfunction ensues, the heart failure process is usually
in an advanced stage involving both systolic and diastolic
function and thus has a poor outcome.
Therapy
Medical treatment in systolic dysfunction (Fig. 5) is pri-
marily based on ACE inhibitors, drugs that are effective
even in asymptomatic patients with an LV ejection fraction
of 35%|161or40% in patients after myocardial infarction'17'.
With further progression of heart failure, diuretics fol-
lowed by digitalis are employed'18'. Beta-blockers in low
doses seem to achieve an additional benefit'19'. Calcium
channel blockers are rarely indicated because of their neg-
ative inotropic effects. Newer calcium antagonists, such as
amlodipine, nisoldipine or felodipine might improve
symptoms of systolic dysfunction'20', but this has to be
proven in large scale trials. Atrial fibrillation and ventricu-
lar tachycardia are preferably treated by amiodarone.
Anticoagulation to prevent systemic embolism is recom-
mended in severe systolic dysfunction, especially in dilated
cardiomyopathy121'. In treatment failure, cardiac transplan-
tation is possible in appropriate patients; otherwise
intractable life-threatening ventricular arrhythmias can be
managed by means of an implantable cardioverter defrib-
rillator.
Data are sparse for medical treatment of diastolic dys-
function. The underlying disease is currently the most
important determinant for therapy. In hypertensive heart
disease for example (Fig. 6), therapy may start with a cal-
cium channel blocker, an ACE inhibitor, or a beta-blocker.
All these drugs have been shown to reduce left ventricular
hypertrophy122'. A diuretic can be added when symptoms
increase, and in advanced stages a combination of these
drugs may be necessary. When atrial fibrillation occurs,
restoration of sinus rhythm is often mandatory and is best
achieved with electric conversion. For prophylaxis of
recurrence, beta-blockers, especially sotalol, which exerts a
class III antiarrhythmic effect, are suitable. Cardiac trans-
plantation is rarely indicated. The antifibrotic action of
spironolactone is currently being investigated: promising
animal data show that spironolactone can prevent myocar-
dial fibrosis123'. Digitalis can worsen LV relaxation and
should be avoided, except in atrial fibrillation.
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